ADC Therapeutics reports Q3 2026 results, restructuring extends cash runway into 2029
The company detailed a PIPE and debt amendment completed in October, ASH 2026 abstracts for ZYNLONTA, and a Japan filing by partner Tanabe Pharma.
ADC Therapeutics SA reported financial results for the third quarter ended September 30, 2026 on November 9, 2026, along with operational updates spanning its balance sheet, pipeline and regulatory efforts for ZYNLONTA (loncastuximab tesirine-lpyl).
In October 2026, the company completed a financial restructuring. it announced a comprehensive strategic financial restructuring that included an $86.6 million private investment in public equity financing with Bain Capital Life Sciences joining existing investors Redmile, TCGX, and Nantahala Capital.1 The PIPE resulted in roughly 12.9 million common shares issued along with 48 million warrants carrying a CHF 0.08 strike price.1 Separately, the company revised its HealthCare Royalty financing agreement to remove a $150 million change-of-control payment, and modified its senior secured loan terms to cut outstanding principal by $68.5 million to $50 million, drop scheduled principal amortization, and eliminate the minimum liquidity covenant.1 The company said these transactions strengthened its capital structure, enhanced strategic optionality and extended the expected cash runway into 2029.1
On the clinical side, five oral presentations at the 68th American Society of Hematology Annual Meeting in December will include updated Phase 1b LOTIS-7 data on ZYNLONTA paired with glofitamab in relapsed or refractory large B-cell lymphoma, full Phase 3 LOTIS-5 results combining ZYNLONTA with rituximab in relapsed or refractory DLBCL, and investigator-initiated data in marginal zone lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia.1
On regulatory progress in Japan, Tanabe Pharma Corporation, formerly Mitsubishi Tanabe Pharma Corporation and described as ADC Therapeutics' Japanese licensing partner, filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare covering ZYNLONTA for relapsed or refractory DLBCL after two or more prior systemic therapies.1 Tanabe Pharma also signed an exclusive sublicensing deal with Nippon Shinyaku Co., Ltd. to commercialize ZYNLONTA in Japan.1
Financially, net product revenue was $21.0 million for the quarter and $59.7 million for the first nine months, up from $15.8 million and $51.2 million in the same 2025 periods.1 Cash and cash equivalents stood at $189.2 million as of September 30, 2026, down from $261.3 million at year-end 2025, primarily reflecting cash used in operations.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.